Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fluoropyrimidine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 194Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EC Approves KEYTRUDAPlus Trastuzumab and Chemotherapy as First-Line Treatment
    EC Approves KEYTRUDAPlus Trastuzumab and Chemotherapy as First-Line Treatment

    29 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230829956930/en

    BUSINESSWIRE
    29 Aug 2023
    Share Share
    FDA approves Taiho's Lonsurf with bevacizumab for metastatic colorectal cancer
    FDA approves Taiho's Lonsurf with bevacizumab for metastatic colorectal cancer

    03 Aug 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/fda-approves-taihos-lonsurf-with-bevacizumab-for-third-line-metastatic-colorectal-cancer/

    Zachary Brennan ENDPTS
    03 Aug 2023
    Share Share
    Merck’s KEYTRUDA Plus Chemotherapy Improved Overall Survival in GEJ
    Merck’s KEYTRUDA Plus Chemotherapy Improved Overall Survival in GEJ

    17 Feb 2023

    // PRESS RELEASE

    https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-alone-in-patients-with-her2-negative-gastric-or-gastroesophageal-junction/

    PRESS RELEASE
    17 Feb 2023
    Share Share
    Seagen Announces FDA Accelerated Approval of TUKYSA with Trastuzumab
    Seagen Announces FDA Accelerated Approval of TUKYSA with Trastuzumab

    19 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221222005382/en/Seagen-Announces-FDA-Accelerated-Approval-of-TUKYSA%C2%AE-tucatinib-in-Combination-with-Trastuzumab-for-People-with-Previously-Treated-RAS-Wild-Type-HER2-Positive-Metastatic-Colorectal-Cancer

    BUSINESSWIRE
    19 Jan 2023
    Share Share
    Agilent Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include ESCC
    Agilent Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include ESCC

    05 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220405005750/en

    BUSINESSWIRE
    05 Apr 2022
    Share Share
    European Commission approves Teysuno in metastatic colorectal cancer
    European Commission approves Teysuno in metastatic colorectal cancer

    31 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/european-commission-approves-teysuno-in-metastatic-colorectal-cancer-301470829.html

    PRNEWSWIRE
    31 Jan 2022
    Share Share